BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 30001523)

  • 1. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
    Ernst JD
    Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology of
    Sia JK; Rengarajan J
    Microbiol Spectr; 2019 Jul; 7(4):. PubMed ID: 31298204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stealth Strategies of
    Naeem MA; Ahmad W; Tyagi R; Akram Q; Younus M; Liu X
    Curr Issues Mol Biol; 2021; 41():597-616. PubMed ID: 33068079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond memory T cells: mechanisms of protective immunity to tuberculosis infection.
    Steigler P; Verrall AJ; Kirman JR
    Immunol Cell Biol; 2019 Aug; 97(7):647-655. PubMed ID: 31141205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycobacterium tuberculosis infection and vaccine development.
    Tang J; Yam WC; Chen Z
    Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The generation of T-cell memory to protect against tuberculosis.
    Counoupas C; Triccas JA
    Immunol Cell Biol; 2019 Aug; 97(7):656-663. PubMed ID: 31127962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against
    Chen Y; Xiao JN; Li Y; Xiao YJ; Xiong YQ; Liu Y; Wang SJ; Ji P; Zhao GP; Shen H; Lu SH; Fan XY; Wang Y
    Front Immunol; 2018; 9():3190. PubMed ID: 30700988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of new tuberculosis vaccine in children.
    Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
    Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status, challenges, and future developments of new tuberculosis vaccines.
    Gong W; Liang Y; Wu X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1697-1716. PubMed ID: 29601253
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ryndak MB; Laal S
    Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering protective immunity against tuberculosis: implications for vaccine development.
    Counoupas C; Triccas JA; Britton WJ
    Expert Rev Vaccines; 2019 Apr; 18(4):353-364. PubMed ID: 30793629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant live vaccine candidates against tuberculosis.
    Kaufmann SH; Gengenbacher M
    Curr Opin Biotechnol; 2012 Dec; 23(6):900-7. PubMed ID: 22483201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of phthiocerol dimycocerosate on CD4(+) T cell priming and persistence during Mycobacterium tuberculosis infection.
    Pinto R; Nambiar JK; Leotta L; Counoupas C; Britton WJ; Triccas JA
    Tuberculosis (Edinb); 2016 Jul; 99():25-30. PubMed ID: 27450001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of clinical models for the evaluation of human TB vaccines.
    O'Shea MK; McShane H
    Hum Vaccin Immunother; 2016 May; 12(5):1177-87. PubMed ID: 26810964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the host immune response to tuberculosis vaccines.
    Fletcher HA
    Vaccine; 2015 Sep; 33(40):5313-5. PubMed ID: 26241949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.
    Sable SB; Posey JE; Scriba TJ
    Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31666281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.